Metamizol (Novalgin®): Das kontroverse Schmerzmittel – Agranulozytose-Risiko, Warnsignale & wann es wirklich gerechtfertigt ist

Contents

1. At a Glance: Key Facts
2. The Controversy: Why Is It Banned in Other Countries?
3. How It Works
4. Licensed Indications — and Where Metamizole Does Not Belong
5. Dosage
6. Agranulocytosis: The Core Risk Explained
7. EMA Safety Review December 2024: The New Rules
8. Warning Signs Every Patient Must Know
9. Further Side Effects
10. Interactions
11. Metamizole Compared: vs. Ibuprofen vs. Paracetamol vs. Diclofenac
12. Pregnancy & Special Groups
13. Real-World Data
14. How brite Supports You
15. Metamizole Experiences: What Patients Really Ask
16. FAQ: Frequently Asked Questions About Metamizole / Novalgin
17. Sources

Metamizole should only be used for licensed indications and under medical supervision. For fever, severe sore throat, or mucosal changes while taking metamizole: stop immediately and see a doctor. This article does not replace medical advice.

1. At a Glance: Key Facts

Metamizole (active substance: metamizole sodium; trade name: Novalgin®, also known as dipyrone) is one of the most potent non-opioid analgesics — and at the same time one of the most controversial. In Germany it is prescription-only and widely used. In the USA, UK, and much of northern Europe it has been banned for decades. The reason: the risk of a rare but life-threatening side effect — agranulocytosis.

2. The Controversy: Why Is It Banned in Other Countries?

Anyone who brings familiar Novalgin drops back from a holiday in Spain or Portugal may be surprised: there, metamizole is sometimes available without a prescription. Anyone asking a British or American doctor about metamizole is likely to be met with incomprehension: in these countries it has been withdrawn from the market for decades. How can the same medication be routinely prescribed in one country and completely banned in another?

The answer lies in a different benefit-risk assessment. Countries that banned metamizole judged the agranulocytosis risk too high for broad use. Germany and other countries reach a different conclusion: with strict indication — only for severe pain that other agents cannot adequately control — metamizole is indispensable. For colic (biliary, renal colic) in particular, it has a unique spasmolytic action that no other analgesic can replicate. And in patients for whom NSAIDs are contraindicated because of cardiac conditions, gastric ulcers, or kidney problems, metamizole fills a therapeutic gap. The December 2024 EMA decision further clarified the framework for its use.

3. How It Works

The precise mechanism of action of metamizole is still not fully understood — which makes it pharmacologically unique. It is converted in the body to active metabolites (primarily 4-methylaminoantipyrine), which appear to act through several pathways simultaneously: by inhibiting prostaglandin synthesis (similar to NSAIDs but with a different profile), by a direct spasmolytic effect on smooth muscle (particularly relevant in colic), and by central pain inhibition via the endogenous cannabinoid system and descending pain-inhibitory pathways in the spinal cord.

This combined mechanism explains why metamizole is particularly effective for certain pain types: visceral pain (colic), post-operative pain, and cancer pain — situations where conventional NSAIDs or paracetamol are often insufficient.

4. Licensed Indications — and Where Metamizole Does Not Belong

This is pharmacologically and legally decisive: metamizole is not an everyday painkiller and not a substitute for ibuprofen or paracetamol (acetaminophen) for mild to moderate pain. It may only be used when other measures are insufficient or contraindicated. This principle is frequently violated in practice.

5. Dosage

6. Agranulocytosis: The Core Risk Explained

Agranulocytosis is the term every metamizole patient must know. It refers to a sudden, dramatic fall in neutrophil granulocytes — the white blood cells responsible for defending against bacterial infections. When these cells fall below 500 per microlitre, the body's own infection defence is practically switched off. Even harmless bacteria can then lead to life-threatening sepsis.

What makes agranulocytosis so dangerous is its unpredictability. It is not dose-dependent — it can occur after the first tablet just as readily as after weeks of trouble-free use. There is no laboratory warning value, no identifiable risk group. The mechanism is immunological: for reasons still unknown, the patient's immune system forms antibodies against metamizole metabolites on the surface of granulocytes and destroys them.

The paradox: metamizole masks the fever it causes

This is the most dangerous feature of the agranulocytosis risk: metamizole is frequently used as a fever reducer. Agranulocytosis causes severe infections which — like any infection — manifest with fever. When a patient takes metamizole for fever and develops agranulocytosis in the process, the metamizole suppresses the fever caused by the agranulocytosis. The warning signal is suppressed. The diagnosis is delayed. The chance of timely treatment diminishes.

This is why regulatory authorities particularly warn against using metamizole routinely as a fever reducer when paracetamol (acetaminophen) or ibuprofen are possible alternatives.

7. EMA Safety Review December 2024: The New Rules

The safety communication of 9 December 2024 — issued following a comprehensive European reassessment by the EMA and implemented by EU Commission decision of 22 November 2024 — changed one important aspect of metamizole therapy practice.

The surprising core finding: routine blood count monitoring is no longer recommended. This initially sounds counterintuitive — shouldn't a medication with a known risk of blood count changes be particularly closely monitored? But the evidence shows: agranulocytosis occurs so suddenly that even weekly blood tests cannot provide reliable early detection. Between a normal blood count on Monday and manifest agranulocytosis on Wednesday, days can pass. Blood testing gives a false sense of security.

Instead, the 2024 decision places the emphasis firmly on systematic patient education: every patient must know the warning signs of agranulocytosis and understand what to do immediately if they occur. This is the only reliable protection — not laboratory monitoring, but informed patients.

8. Warning Signs Every Patient Must Know

Particularly important: these warning signs apply even after stopping. Agranulocytosis can manifest days after the last metamizole tablet. Anyone who has taken metamizole and subsequently develops fever with a sore throat must act immediately — even if they have already stopped the medication.

9. Further Side Effects

In addition to agranulocytosis, metamizole has further clinically relevant side effects, which are well documented and have been addressed in part by their own regulatory safety communications (2020: hepatotoxicity).

10. Interactions

Metamizole has some clinically relevant interactions, of which the combination with methotrexate is the most important and most dangerous. Check all combinations with the interaction check.

11. Metamizole Compared: vs. Ibuprofen vs. Paracetamol vs. Diclofenac

Metamizole has a unique profile — it is neither an NSAID nor a simple analgesic like paracetamol. It fills a specific niche that no other painkiller can cover. The comparison helps to understand the therapeutic rationale.

The most important situations in which metamizole is the logical choice: for biliary or renal colic (unique spasmolytic action that no other oral analgesic has), post-operatively when NSAIDs are contraindicated because of cardiac, renal, or gastric problems, and for severe pain under SSRI therapy — since metamizole, unlike NSAIDs, does not increase bleeding risk. For mild to moderate everyday pain, metamizole is not appropriate — here the rule applies: paracetamol (acetaminophen) or ibuprofen first.

12. Pregnancy & Special Groups

During breastfeeding, metabolites of metamizole pass into breast milk. Breastfeeding during use and for up to 48 hours after is not recommended. In children, metamizole is licensed from 3 months of age (drops for weight-adjusted dosing), but always with strict indication.

13. Real-World Data: What brite Users Report

The brite app shows two dominant problems with metamizole: lack of awareness of warning signs, and self-medication with leftover supplies.

Self-medication with leftover supplies is a particular problem: a patient receives metamizole after surgery but takes only half the prescribed course. They keep the rest — and take it months later for a headache. This is dangerous for several reasons: headache is not a licensed indication. A new course without medical consultation means no education about warning signs. And the risk with re-exposure may be increased. Please do not store metamizole leftovers or pass them on to others.

14. How brite Supports You with Metamizole

• Agranulocytosis education: Actively informs about warning signs (fever, sore throat, mucosal lesions) whenever metamizole is recorded.
• Indication check: Checks whether the stated indication is licensed for metamizole. → Interaction check
• Re-prescription warning: Warns on re-recording after a previous episode of agranulocytosis.
• Self-medication warning: Flags uncontrolled use from leftover supplies.
• Aspirin interaction: Detects potential reduction in aspirin's antiplatelet effect. → Dose reminder
• Digital medication plan: → Create medication plan

Metamizole Experiences: What Patients Really Ask

Why is Novalgin banned in the USA and UK? The USA withdrew metamizole from the market in 1977; the UK followed. The reason: the agranulocytosis risk was judged too great — particularly at a time without today's options for close patient education. Germany assesses the benefit-risk balance differently, because metamizole fills a therapeutic gap for colic and severe pain that other agents cannot fill. This assessment is medically defensible — but only with strict indication.

Novalgin agranulocytosis symptoms — how do I recognise them? The classic warning signs: sudden onset of fever (especially above 38.5°C / 101.3°F), severe sore throat, painful ulcers or changes to the mucous membranes (mouth, nose, genital or anal area), and a sudden marked deterioration in general wellbeing. Important: do not wait for the next appointment — act immediately, stop metamizole, and go to A&E or call a doctor urgently.

Novalgin urine red — is that dangerous? No — the reddish/orange discolouration of urine under metamizole is harmless. It is caused by the metabolite rubazoic acid, a pigment with no clinical significance. It is not blood and not a sign of kidney damage. If still in doubt, a urine test can be done by a doctor — but the appearance alone is no cause for alarm.

Metamizole for headaches — can I take it? No — metamizole is not licensed for mild to moderate headaches. First choice for headaches: ibuprofen 400 mg or paracetamol (acetaminophen). Self-medication with Novalgin leftovers for headaches is one of the most common dangerous misuses.

Novalgin for colic — why does it work so well for renal colic? Because metamizole has both analgesic and spasmolytic action — it relaxes smooth muscle. Colic arises from spasms of the ureteric or bile duct musculature. No other oral analgesic has this spasmolytic component. This makes metamizole the clinically superior agent for colic — and it is one of the few situations where its use is clearly justified.